Second primary malignancies following thyroid cancer: A population-based study in Taiwan

European Journal of Endocrinology

Volumn 169, Issue 5, 2013, Pages 577-585

  Lu, Chang Hsien ^a,b,c   Lee, Kuan Der ^a,b,c   Chen, Ping Tsung ^a,b,c   Chen, Chih Cheng ^a,b,c   Kuan, Feng Che ^a,b,c   Huang, Cih En ^a   Chen, Miao Fen ^a,b,c   Chen, Min Chi ^d  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b CHANG GUNG UNIVERSITY   (Taiwan)

^c CHANG GUNG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Taiwan)

^d CHANG GUNG UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; BLADDER CANCER; BRAIN CANCER; BREAST CANCER; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER REGISTRY; CANCER RISK; CANCER SURVIVAL; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HIGH RISK POPULATION; HUMAN; LEUKEMIA; LUNG CANCER; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; NASOPHARYNX CANCER; OVERALL SURVIVAL; POPULATION RESEARCH; PRIMARY TUMOR; PRIORITY JOURNAL; RISK ASSESSMENT; SALIVARY GLAND CANCER; SECOND CANCER; SURVIVAL TIME; TAIWAN; THYMUS CANCER; THYROID CANCER;

ADULT; AGE FACTORS; AGE OF ONSET; AGED; AGED, 80 AND OVER; ASIAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; NEOPLASMS, SECOND PRIMARY; REGISTRIES; RISK; SEX FACTORS; SURVIVAL; TAIWAN; THYROID NEOPLASMS;

EID: 84885157953     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-13-0309     Document Type: Article

References (38)

1. Hundahl SA, Fleming ID, Fremgen AM & Menck HR. A National Cancer Data Base report on 53, 856 cases of thyroid carcinoma treated in the U. S., 1985-1995. Cancer 1998 83 2638-2648. (doi:10.1002/(SICI) 1097-0142 (19981215) 83:12 <2638::AID-CNCR31 > 3.0. CO;2-1)
2. Jemal A, Siegel R, Xu J & Ward E. Cancer Statistics, 2010. CA: A Cancer Journal for Clinicians 2010 60 277-300. (doi:10.3322/caac.20073)
3. Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, Waldron W, Altekruse SF, Kosary CL, Ruhl J, Tatalovich Z et al. (eds). In SEER Cancer Statistics Review, 1975-2008. Bethesda, MD: National Cancer Institute (http://seer.cancer. gov/csr/1975-2008/, based on November 2010 SEER data submission, posted to the SEER web site), 2011.
4. Davies L & Welch HG. Increasing incidence of thyroid cancer in the United States, 1973-2002. Journal of the American Medical Association 2006 295 2164-2167. (doi:10.1001/jama.295.18.2164)
5. Ferlay J, Bray F, Pisani P & Parkin DM. In GLOBOCAN 2000: Cancer Incidence, Mortality and Prevalence Worldwide, v 1.0. IARC Cancer Base No. 5. Lyon: IARC Press (available at: http://wwwdep.iarc.fr/globocan/globocan.html).
6. Kilfoy BA, Zheng T, Holford TR, Han X, Ward MH, Sjodin A, Zhang Y, Bai Y, Zhu C, Guo GL et al. International patterns and trends in thyroid cancer incidence, 1973-2002. Cancer Causes & Control 2009 20 525-531. (doi:10.1007/s10552-008-9260-4)
7. Burgess JR. Temporal trends for thyroid carcinoma in Australia: an increasing incidence of papillary thyroid cancer (1982-1997). Thyroid 2000 12 141-149. (doi:10.1089/1050725027535 22374)
8. Bureau of Health Promotion, Department of Health, Taiwan (available at: http://www.bhp. doh.gov. tw/BHPNET/Portal/Statistics.aspx).
9. Verkooijen HM, Fioretta G, Pache JC, Franceschi S, Raymond L, Schubert H & Bouchardy C. Diagnostic changes as a reason for the increase in papillary thyroid cancer incidence in Geneva, Switzerland. Cancer Causes & Control 2003 14 13-17. (doi:10. 1023/A:1022593923603)
10. La Vecchia C, Ron E, Franceschi S, Dal Maso L, Mark SD, Chatenoud L, Braga C, Preston-Martin S, McTiernan A, Kolonel L et al. A pooled analysis of case-control studies of thyroid cancer. III. Oral contraceptives, menopausal replacement therapy and other female hormones. Cancer Causes & Control 1999 10 157-166. (doi:10.1023/A:1008832513932)
11. Clavel-Chapelon F, Guillas G, Tondeur L, Kernaleguen C & Boutron-Ruault MC. Risk of differentiated thyroid cancer in relation to adult weight, height, and body shape over life: the French E3N cohort. International Journal of Cancer 2010 126 2984-2990. (doi:10.1002/ijc.25066)
12. Ron E, Lubin JH, Shore RE, Mabuchi K, Modan B, Pottern LM, Schneider AB, Tucker MA & Boice JD Jr. Thyroid cancer after exposure to external radiation: a pooled analysis of seven studies. Radiation Research 1995 141 259-277. (doi:10.2307/3579003)
13. Zuurbier M, Leijs M, Schoeters G, ten Tusscher G & Koppe JG. Children's exposure to polybrominated diphenyl ethers. Acta Paediatrica. Supplementum 2006 95 65-70. (doi:10.1080/08035320600886299)
14. Colonna M, Grande E, Jonasson JG & Eurocare Working Group. Variation in relative survival of thyroid cancers in Europe: results from the analysis on 21 countries over the period 1983-1994 (EUROCARE-3 study). European Journal of Cancer 2006 42 2598-2608. (doi:10.1016/j.ejca.2006.04.026)
15. Rubino C, de Vathaire F, Dottorini ME, Hall P, Schvartz C, Couette JE, Dondon MG, Abbas MT, Langlois C & Schlumberger M. Second primary malignancies in thyroid cancer patients. British Journal of Cancer 2003 89 1638-1644. (doi:10.1038/sj.bjc. 6601319)
16. Berthe E, Henry-Amar M, Michels JJ, Rame JP, Berthet P, Babin E, Icard P, Samama G, Galateau-Salle F, Mahoudeau J et al. Risk of second primary cancer following differentiated thyroid cancer. European Journal of Nuclear Medicine and Molecular Imaging 2004 31 685-691. (doi:10.1007/s00259-003-1448-y)
17. Ronckers CM, McCarron P & Ron E. Thyroid cancer and multiple tumors in the SEER cancer registries. International Journal of Cancer 2005 117 281-288. (doi:10.1002/ijc.21064)
18. Verkooijen RB, Smit JW, Romijn JA & Stokkel MP. The incidence of second primary tumors in thyroid cancer patients is increased, but not related to treatment of thyroid cancer. European Journal of Endocrinology 2006 155 801-806. (doi:10.1530/eje.1.02300)
19. Sandeep TC, Strachan MW, Reynolds RM, Brewster DH, Scelo G, Pukkala E, Hemminiki K, Anderson A, Tracey E, Friis S et al. Second primary cancers in thyroid cancer patients: a multinational record linkage study. Journal of Clinical Endocrinology and Metabolism 2006 91 1819-1825. (doi:10.1210/jc.2005- 2009)
20. Brown AP, Chen J, Hitchcock YJ, Szabo A, Shrieve DC & Tward JD. The risk of second primary malignancies up to three decades after the treatment of differentiated thyroid cancer. Journal of Clinical Endocrinology and Metabolism 2008 93 504-515. (doi:10.1210/jc.2007-1154)
21. Berrington de Gonzalez A, Curtis RE, Kry SF, Glibert E, Lamart S, Berg CD, Stovall M & Ron E. Proportion of second cancers attributable to radiotherapy treatment in adults: a cohort study in the SEER cancer registries. Lancet Oncology 2012 12 353-360. (doi:10.1016/S1470-2045 (11) 70061-4)
22. Kim C, Bi X, Pan D, Chen Y, Carling T, Ma S, Udelsman R & Zhang Y. Risk of second cancer after diagnosis of thyroid cancer primary is elevated in microcarcinoma. Thyroid 2013 23 5 75-582. (doi:10.1089/thy.2011.0406)
23. Ishikawa K, Noguchi S, Tanaka K, Fukuda A & Hirohata T. Second primary neoplasms in thyroid cancer patients. Japanese Journal of Cancer Research 1996 87 232-239. (doi:10.1111/j.1349-7006. 1996.tb00211.x)
24. Lang BH, Wong IO, Wong KP, Cowling BJ & Wan KY Risk of second primary malignancy in differentiated thyroid carcinoma treated with radioactive iodine therapy. Surgery 2012 151 844-850. (doi:10.1016/j.surg.2011.12.019)
25. Lang BH, Lo CY, Wong IO & Cowling BJ. Impact of second primary malignancy on outcome of differentiated thyroid carcinoma. Surgery 2010 148 1191-1196. (doi:10.1016/j.surg.2010.09.022)
26. Lang BH & Wong KP. Risk factors for nonsynchronous second primary malignancy and related death in patients with differentiated thyroid carcinoma. Annals of Surgical Oncology 2011 18 3559-3565. (doi:10.1245/s10434-011-1777-1)
27. Slee VN. The International Classification of Diseases: ninth revision (ICD-9). Annals of Internal Medicine 1978 88 424-426. (doi:10.7326/0003-4819-88- 3-424)
28. Muir CS & Percy C. Cancer registration: principles and methods. Classification and coding of neoplasms. IARC Scientific Publications 1991 95 64-81.
29. Breslow NE & Day NE. Statistical methods in cancer research. Volume II - the design and analysis of cohort studies. IARC Scientific Publications 1987 82 1-406.
30. Kalbfleisch J & Prentice PR. In The Analysis of Failure Time Data, vol 2, 2nd edn, pp 203-215. New York: John Wiley & Sons, 2002.
31. Gray R. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Annals of Statistics 1988 16 1141-1154. (doi:10.1214/aos/1176350951)
32. Lin JD, Lin KJ, Chao TC, Hseuh C, Tsang NM & Huang BY. Clinical presentations of thyroid cancer patients with multiple primary cancers. Journal of Endocrinological Investigation 2011 34 824-830. (doi:10.3275/7747)
33. Adjadj E, Rubino C, Shamsaldim A, Le MG, Schlumberger M & de Vathaire F. The risk of multiple primary breast and thyroid carcinomas. Cancer 2003 98 1309-1317. (doi:10.1002/cncr. 11626)
34. Chuang SC, Hashibe M, Yu GP, Le AD, Cao W, Hurwitz EL, Rao JY, Neugut AI & Zhang ZF. Radiotherapy for primary thyroid cancer as a risk factor for second primary Cancer Letters 2006 238 42-52. (doi:10.1016/j.canlet.2005.06.015)
35. Sawka AM, Thabane L, Parlea L, Ibrahim-Zada I, Tsang RW, Brierley JD, Straus S, Ezzat S & Goldstein DP. Second primary malignancy after radioactive iodine treatment for thyroid cancer: a systemic review and meta-analysis. Thyroid 2009 19 451-457. (doi:10.1089/thy 2008.0392)
36. Gal TJ, Huang WY, Chen C, Hayes RB & Schwartz SM. DNA repair gene polymorphisms and risk of second primary neoplasms and mortality in oral cancer patients. Laryngoscope 2005 115 2221-2231. (doi:10.1097/01.mlg.0000183736.96004. f7)
37. Erculj N, Faganel Kotnik B, Debeljak M, Jazbec J & Dolzan V DNA repair polymorphisms influence the risk of second neoplasm after treatment of childhood acute lymphoblastic leukemia. Journal of Cancer Research and Clinical Oncology 2012 138 1919-1930. (doi:10.1007/s00432-012-1265-4)
38. Feller L & Lemmer J. New 'second primary' cancers. SADJ 2012 67 175-178.